Endemic mycoses in immunocompromised hosts

Current Infectious Disease Reports

Volumn 15, Issue 6, 2013, Pages 536-543

  Malcolm, Trent R ^a   Chin Hong, Peter V ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blastomyces dermatitidis; Coccidioides immitis; Coccidioides posadasii; Endemic fungi; Endemic mycoses; Histoplasma capsulatum; Immunocompromised; Immunosuppressed; Paracoccidioides brasiliensis; Penicillium marneffei; Sporothrix schenkii

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CIPROFLOXACIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FARNESOL; FUNGUS VACCINE; ITRACONAZOLE; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VORICONAZOLE;

ARTICLE; BLASTOMYCOSIS; COCCIDIOIDOMYCOSIS; DIMORPHIC FUNGAL INFECTION; ENVIRONMENTAL CHANGE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL; HISTOPLASMOSIS; HUMAN; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INFECTION PREVENTION; PENICILLIOSIS; SENSITIVITY AND SPECIFICITY; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS;

EID: 84890801362     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0387-4     Document Type: Article

References (66)

1. Hsu LY, Ng ES, Koh LP. Common and emerging fungal pulmonary infections. Infect Dis Clin North Am. 2010;24(3):557-77.
2. Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am. 2006;20(3):645-62. vii.
3. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36(1):1-53.
4. Grim SA et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis. 2012;14(1):17-23.
5. Ramos-e-Silva M et al. Systemic mycoses in immunodepressed patients (AIDS). Clin Dermatol. 2012;30(6):616-27.
6. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69(11):1403-15.
7. Hu Y et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013;175(1-2):57-67.
8. Le T et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. 2011;52(7):945-52.
9. Baddley JW et al. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn Microbiol Infect Dis. 2008;62(2):151-6.
10. Chapman SW et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(12):1801-12.
11. Huang JY et al. Coccidioidomycosis-associated Deaths, United States, 1990-2008. Emerg Infect Dis. 2012;18(11):1723-8.
12. Pappas PG et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101-11.
13. Blair JE et al. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia. 2006;162(5):317-24.
14. Centers for Disease Control and Prevention (CDC). Increase in reported coccidioidomycosis - United States, 1998-2011. MMWR Morb Mortal Wkly Rep. 2013;62(12):217-21.
15. Dasmasceno LS et al. Disseminated histoplasmosis and aids: relapse and late mortality in endemic area in North-Eastern Brazil. Mycoses. 2013;56(5):520-6.
16. Taroumian S et al. Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken). 2012;64(12):1903-9.
17. Rangwala F et al. Histoplasmosis and penicilliosis among HIV-infected Thai patients: a retrospective review. Southeast Asian J Trop Med Public Health. 2012;43(2):436-41.
18. Cuellar-Rodriguez J et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis. 2009;49(5):710-6.
19. Freifeld AG et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis. 2005;7(3-4):109-15.
20. Gauthier GM et al. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis. 2007;9(4):310-7.
21. Kontoyiannis DP et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091-100.
22. Edwards LB et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis. 1969;99(4):1-132.
23. Gautam R et al. Identifying areas of high risk of human exposure to coccidioidomycosis in Texas using serology data from dogs. Zoonoses Public Health. 2013;60(2):174-81.
24. Singh N et al. Donor-derived fungal infections in organ transplant recipients: guidelines of the American Society of Transplantation, infectious diseases community of practice. Am J Transplant. 2012;12(9):2414-28.
25. Dierberg KL et al. Donor-derived organ transplant transmission of coccidioidomycosis. Transpl Infect Dis. 2012;14(3):300-4.
26. Tang YW et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn Microbiol Infect Dis. 2006;54(4):283-7.
27. Connolly P et al. Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay. Clin Vaccine Immunol. 2012;19(1):53-6.
28. Hage CA et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011;53(5):448-54.
29. Mendoza N, Blair JE. The utility of diagnostic testing for active coccidioidomycosis in solid organ transplant recipients. Am J Transplant. 2013;13(4):1034-9.
30. Babady NE et al. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol. 2011;49(9):3204-8.
31. Koepsell SA, Hinrichs SH, Iwen PC. Applying a real-time PCR assay for Histoplasma capsulatum to clinically relevant formalin-fixed paraffin-embedded human tissue. J Clin Microbiol. 2012;50(10):3395-7.
32. Sidamonidze K et al. Real-time PCR assay for identification of Blastomyces dermatitidis in culture and in tissue. J Clin Microbiol. 2012;50(5):1783-6.
33. Elias NA et al. Rapid identification of Histoplasma capsulatum directly from cultures by multiplex PCR. Mycopathologia. 2012;174(5-6):451-6.
34. Dantas KC et al. The use of nested Polymerase Chain Reaction (nested PCR) for the early diagnosis of Histoplasma capsulatum infection in serum and whole blood of HIV-positive patients. An Bras Dermatol. 2013;88(1):141-3.
35. Liao MH, Lin JF, Li SY. Application of a multiplex suspension array for rapid and simultaneous identification of clinically important mold pathogens. Mol Cell Probes. 2012;26(5):188-93.
36. Liu X, Zhang Z, Hou B, Wang D, Sun T, Li F, et al. Rapid identification of Sporothrix schenckii in biopsy tissue by PCR. J Eur Acad Dermatol Venereol. 2012. doi: 10.1111/jdv.12030
37. Inglis DO et al. Comparative transcriptomics of infectious spores from the fungal pathogen Histoplasma capsulatum reveals a core set of transcripts that specify infectious and pathogenic states. Eukaryot Cell. 2013;12(6):828-52.
38. Galgiani JN et al. Coccidioidomycosis. Clin Infect Dis. 2005;41(9):1217-23.
39. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007;20(1):115-32.
40. Wheat LJ et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807-25.
41. Abadio AK et al. Comparative genomics allowed the identification of drug targets against human fungal pathogens. BMC Genomics. 2011;12:75.
42. Brilhante RS et al. Ciprofloxacin shows synergism with classical antifungals against Histoplasma capsulatum var. capsulatum and Coccidioides posadasii. Mycoses. 2013;56(3):397-401.
43. Brilhante RS et al. Effect of farnesol on growth, ergosterol biosynthesis, and cell permeability in Coccidioides posadasii. Antimicrob Agents Chemother. 2013;57(5):2167-70.
44. Cole GT et al. A vaccine against coccidioidomycosis is justified and attainable. Med Mycol. 2004;42(3):189-216.
45. Deepe Jr GS. Preventative and therapeutic vaccines for fungal infections: from concept to implementation. Expert Rev Vaccines. 2004;3(6):701-9.
46. Deepe Jr GS, Wuthrich M, Klein BS. Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity. Med Mycol. 2005;43(5):381-9.
47. Hung CY et al. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine. 2012;30(31):4681-90.
48. Magalhaes A et al. Prophylactic and therapeutic vaccination using dendritic cells primed with peptide 10 derived from the 43-kilodalton glycoprotein of Paracoccidioides brasiliensis. Clin Vaccine Immunol. 2012;19(1):23-9.
49. Travassos LR, Taborda CP. New advances in the development of a vaccine against paracoccidioidomycosis. Front Microbiol. 2012;3:212.
50. Wuthrich M et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J Clin Invest. 2011;121(2):554-68.
51. Xue J et al. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect Immun. 2009;77(8):3196-208.
52. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336(6082):647.
53. Nanjappa SG et al. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune deficient hosts lacking CD4+ T cells. PLoS Pathog. 2012;8(7):e1002771.
54. Nanjappa SG et al. Protective antifungal memory CD8(+) T cells are maintained in the absence of CD4(+) T cell help and cognate antigen in mice. J Clin Invest. 2012;122(3):987-99.
55. Ison MG et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. 2009;9(8):1929-35.
56. Blodget E et al. Donor-derived Coccidioides immitis fungemia in solid organ transplant recipients. Transpl Infect Dis. 2012;14(3):305-10.
57. Brugiere O et al. Coccidioidomycosis in a lung transplant recipient acquired from the donor graft in France. Transplantation. 2009;88(11):1319-20.
58. Carvalho C et al. Cerebral coccidioidomycosis after renal transplantation in a non-endemic area. Transpl Infect Dis. 2010;12(2):151-4.
59. Wright PW et al. Donor-related coccidioidomycosis in organ transplant recipients. Clin Infect Dis. 2003;37(9):1265-9.
60. Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and lung transplantation. Transplantation. 2011;92(7):717-21.
61. Tripathy U et al. Donor transfer of pulmonary coccidioidomycosis in lung transplantation. Ann Thorac Surg. 2002;73(1):306-8.
62. Garzoni C, Ison MG. Uniform definitions for donor-derived infectious disease transmissions in solid organ transplantation. Transplantation. 2011;92(12):1297-300.
63. Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011;11(6):1123-30.
64. Anstead GM, Graybill JR. Coccidioidomycosis. Infect Dis Clin North Am. 2006;20(3):621-43.
65. Travassos LR, Taborda CP, Colombo AL. Treatment options for paracoccidioidomycosis and new strategies investigated. Expert Rev Anti Infect Ther. 2008;6(2):251-62.
66. Vasquez-del-Mercado E, Arenas R, Padilla-Desgarenes C. Sporotrichosis. Clin Dermatol. 2012;30(4):437-43.